Executive Team & Board of Directors
Steven Perrin, PhD
Founder & CEO
Dr. Perrin has twenty years of drug development experience holding positions at the Hoechst-Ariad Genomics Center, Aventis Pharmaceuticals, and as Director of Molecular Profiling at Biogen Idec. He joined the ALS Therapy Development Institute in 2007 to develop and manage a scientific and business strategy to bring effective treatments to the clinic for ALS patients. Over the past decade he has spearheaded the architectural design and execution of the world’s largest ALS Drug development Program bridging preclinical and clinical programs. He has created a novel business model bridging the philanthropic non-profit research community with for-profit medicine, including the co-founding of Anelixis Therapeutics. Dr. Perrin received a Ph.D. in biochemistry from the Boston University Medical Center. He is a frequent invited participant and speaker in international conferences on computational biology, genomics, drug development and neurodegeneration.
Vice President of Clinical Operations & Compliance
Pamela N. Gustafson, MPH, PMP., is the Vice President of Clinical Operations & Compliance at Anelixis Therapeutics. Ms. Gustafson has over 30 years of professional experience in clinical operations in the biotechnology and pharmaceutical industry.
Ms. Gustafson has a proven ability to plan and manage drug development programs across multiple indications and phases of clinical development. She has extensive experience in building and directing multidisciplinary teams to meet and exceed clinical trial objectives.
Prior to joining Anelixis, Ms. Gustafson was Vice President of Clinical Research at Proteon Therapeutics. She spent thirteen years at Proteon building a clinical development team and moving Proteon’s lead clinical development program in dialysis vascular access and peripheral artery disease indications from first in human studies through pivotal phase 3 studies.
Ms. Gustafson has held Clinical Development positions at Trine Pharmaceuticals where she was Director of Clinical Operations and held Clinical Project Management positions at LeukoSite and PAREXEL.
Ms. Gustafson has a Bachelor of Arts in Psychobiology from Wheaton College and a Masters of Public Health in Biostatistics and Epidemiology from Boston University.
Augie & Lynne Nieto
Augie Nieto Board Chairman
A pioneer in the fitness industry, Augie Nieto co-founded Life Fitness, a manufacturer of cardiovascular and strength training fitness equipment, in 1980. Over the course of 25 years, he grew the company to be the largest commercial manufacturer of fitness equipment in the world. In 2005, Augie was diagnosed with amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). Augie along with his wife, Lynne, founded the Augie's Quest initiative in 2006. He currently serves as chairman of Octane Fitness, is on the board of Curves & Jenny Craig, and is the Chairman of the Board of the ALS Therapy Development Institute.
Mr. Ogier has more than thirty years of experience developing therapeutic medical products ranging from pharmaceuticals to medical devices, stem and immune cell therapies and gene therapies. Following receipt of a BA (chemistry) from Williams College and an MBA from the Yale School of Management, he served nearly a decade with Baxter Healthcare Corporation in marketing and business development roles supporting the global adoption of bone marrow and adult stem cell transplantation before joining Aastrom Biosciences, where he served as VP Marketing and supported the company's successful IPO in 1997. He was subsequently President and CEO of Eligix (sold to BioTransplant in 2001), Genetix Pharmaceuticals (renamed bluebird bio, Nasdaq: BLUE), and he was President/CEO and co-founder of Acetylon Pharmaceuticals (sold to Celgene in 2016) and of Regenacy Pharmaceuticals (spun out of Acetylon at the time of the Celgene acquisition). Mr. Ogier currently continues as a director of Regenacy Pharmaceuticals and also serves as a director of Thetis Pharmaceuticals, Biothera Pharmaceuticals, and Katahdin Pharmaceuticals.
Preclinical & Clinical Development Team
- Maeve McNally, Director Program Management & Executive Assistant to CEO & Founder
- Patricia Williams, Regulatory Affairs
- Joy Cavagnaro, Ph.D., DABT, RAC (Toxicology)
- John Bennan, MBA (CMC, Quality Assurance)
- Stephen Notarnicola, Ph.D. (CMC, Manufacturing)
- Fred Taylor, Ph.D. (Protein Biochemistry)
- Ellen Stark, Ph.D., Antibody Engineering
Clinical Advisory Board
ALS CLINICAL ADVISORY BOARD
- Merit E Cudkowicz, M.D. (Massachusetts General Hospital, Harvard Medical School)
- Jonathan Katz, M.D. (Forbes Norris MDA/ALS Research Center
- James D. Berry, M.D. (MGH Neurological Clinical Research Institute)
- Jeremy M. Shefner, M.D., Ph.D. (Barrow Neurological Institute)
- Angela S. Williams, M.D. (Montreal Neurologic Institute, McGill University)
T1D CLINICAL ADVISORY BOARD
- Camillo Ricordi, M.D., Diabetes Research Institute University of Miami